A Stable Clinical Trial Study Team with Trial Legacy Capability Makes All the Difference
The smaller, niche CRO that is well managed, with stable clinical trial study teams that provide trial legacy capability, and…
Why it Matters to Mid-Size Study Sponsors that Your CRO Acts Like a SMO – Case in Point
Valuable activities SMOs and CROs can provide sponsors are identification, activation, and engagement. Ideally, study sponsors can gain: rapid patient…
25 Years of Unparalleled Canadian Oncology Clinical Research Experience
Scimega Research, Canada’s premier oncology contract research organization (CRO), was founded twenty-five years ago by two dynamic entrepreneurs, Denise Deakin…
Assessing the Canadian Landscape for Cancer Research
Canada’s world-class researchers and diverse patient population make it one of the top 6 countries in the world for enrollment of…
eTMF Best Practice for a Lean Team
The TMF is the official record of the clinical study for Regulatory Authorities, be it the FDA, Health Canada, or…
Recovering a Derailed Clinical Trial – Best Practices
Partnerships sometimes do not work out as intended. For medium size and smaller biotech companies enlisting the services of a…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…